Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Effect on Endothelial Progenitor Cells in HOCM
NCT02674958Phase 3Terminated
- Sponsor
- University of Ottawa Heart Institute
- Start
- May 2016
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in Hypertrophic Obstructive Cardiomyopathy (HOCM) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Maximum circulating endothelial progenitor cells as a ratio to baseline at 7 days. Started May 2016; status: terminated.
02
Drugs
aspirin
03
Conditions
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Beyond the preview
Go deeper on NCT02674958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674958.